The direct causes of ALF included herbal medication in two patients, SAE of CHB in two, veno-occlusive AZD2281 manufacturer disease in one, extensive radiation-induced liver disease in one, and indeterminate in one. The mean ± standard deviation (SD) weight of the 44 explanted livers in the LT group was 850 ± 378 g. There was no difference in mean weight between the 12 patients with SAE of CHB and the 32 other patients (870

± 428 g versus 843 ± 366 g, P = 0.84). Pathological examination of the explants showed massive or submassive necrosis in all patients and moderate to marked hepatitis in 33 patients (75%). Bridging fibrosis was observed in 23 patients (52.3%), and no or minimal fibrosis in the remainder. No patients had definite features of cirrhosis. The proportion of patients selleck chemicals llc with bridging fibrosis did not differ significantly between patients with SAE of CHB and others

(66.7% versus 46.9%, P = 0.24). Overall patient survival was 42.7% (47 of 110 patients). All 11 patients with contraindications to LT died within 10 weeks of diagnosis (Fig. 3). Of the 55 patients in the no-LT group, 45 (82%) died while awaiting a graft, with a median time from diagnosis to death of 7 days (IQR 4-11 days). Of the 49 patients in the no-LT group who had grade 1 or 2 encephalopathy at enrollment, only six (12.2%) remained at encephalopathy grade 1 or 2, and all six recovered spontaneously. In contrast, 43 (87.8%) of these 49 patients progressed to grade 3 or 4, with only four (9.3%) recovering

spontaneously. All of the survivors (n = 10, 18%) in the no-LT group recovered fully and maintained normal liver function after a median follow-up period of 1,277 days (range, 855–1,841 days). Among the 56 patients who died without transplantation, the most common cause Sirolimus of death was cerebral edema (46%) followed by infection (43%). All patients in the LT group progressed to grade 3 or 4 encephalopathy before receiving LT. Four patients received liver grafts from deceased donors on days 2, 5, 6, and 10, respectively, after diagnosis. The median time from diagnosis to adult LDLT was 2.5 days (range, 0–26 days). The 1-year patient survival rate of the adult LDLT group was 85% (34 of 40 patients), significantly higher than that of the no-LT group (P < 0.01), but similar to that of the DDLT group (75%, P > 0.05; Fig. 3). The 1-year graft survival rate for the adult LDLT group was the same as the patient survival rate. Six adult LDLT patients, including one who received a dual-graft and one DDLT patient, died within 6 months as a result of brain edema (n = 2), systemic infection (n = 4), or bleeding (n = 1). One LDLT patient underwent a second transplantation for graft failure caused by acute cellular rejection, but later died of fungal pneumonia and sepsis. None of the 1-year survivors in the LT group (n = 37) died within a median follow-up period of 1,168 days (range, 465–1,989 days).